MedTrace Logo

The Effectiveness and Safety of Dupilumab in Children with Asthma in China: a Real-world Study

NCT06851403 · Status: ENROLLING_BY_INVITATION · Type: OBSERVATIONAL · Enrollment: 213

Last updated 2025-02-28

No results posted yet for this study

Summary

Observe the changes of type II inflammation markers, lung function, and symptom scores in asthmatic patients aged 6 to 14 during the use of dupilumab to analyze its efficacy.

Conditions

  • Asthma in Children

Interventions

DRUG

Dupilumab

initial injection of 600 mg, followed by maintenance injections of 300 mg every four weeks

Sponsors & Collaborators

  • Guangzhou Institute of Respiratory Disease

    lead OTHER

Eligibility

Min Age
4 Years
Max Age
16 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-30
Primary Completion
2025-12-30
Completion
2025-12-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06851403 on ClinicalTrials.gov